Bristol Myers Squibb stock gains as Zacks lifts Q3 EPS forecast and guidance stays in focus
Published on 09/15/2026 at 15:03 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Bristol Myers Squibb stock (ISIN US0897961004) most recently closed at USD 64.08 on the New York Stock Exchange on September 14, 2026, leaving the shares a few dollars below the prevailing analyst consensus price target around the mid-USD 60s and putting earnings expectations back into the spotlight for investors.
Earnings forecasts edge higher for 2026
According to MarketBeat on September 15, 2026, Zacks Research raised its estimate for Bristol Myers Squibb’s non-GAAP earnings per share in the third quarter of 2026 to USD 1.55 from a prior forecast of USD 1.54, a modest but positive revision that underscores a constructive view on the near-term profit trajectory. In the same overview, the full-year 2026 consensus EPS estimate stands at about USD 6.95, which aligns closely with the company’s own non-GAAP EPS guidance range of USD 6.75 to USD 7.00 for the fiscal year 2026 as reported by earlier data from Ad-hoc-news.
That guidance implies that, if Bristol Myers Squibb delivers EPS at the upper end of USD 7.00 in 2026, the current consensus of USD 6.95 would be only USD 0.05 below the top of the company’s band, suggesting that analysts broadly expect the group to land toward the higher half of its own forecast range. For investors, the narrow gap between external estimates and internal guidance is an important signal that major surprises on earnings may be less likely in the near term, even as product cycles and patent exposures remain critical drivers.
Recent quarterly results and revenue comparison
As MarketBeat notes in the same September 15, 2026 report, Bristol Myers Squibb’s latest reported quarterly figures came in ahead of market expectations, with the company posting non-GAAP EPS of USD 2.04 versus a consensus estimate of USD 1.60 for that quarter, and revenue of USD 12.97 billion compared with the analysts’ forecast that was lower. The EPS beat of USD 0.44 against consensus represents a roughly 27.5 percent upside versus the expected USD 1.60, underlining the company’s capacity to convert its portfolio into earnings in the recent reporting period.
The revenue figure of USD 12.97 billion for that latest quarter, while not directly paired with a consensus line in the same snippet, shows the scale at which Bristol Myers Squibb is currently operating. Even without a precise year-over-year comparison in the available data, the combination of double-digit-billion revenue and a significant EPS beat provides a tangible backdrop for the upgraded Zacks forecast. For many shareholders, such a performance in the most recent quarter of fiscal 2026 will be a key reference point when assessing whether the EPS range of USD 6.75 to USD 7.00 for the full year remains attainable.
Analyst consensus and diverging views on the stock
In terms of broader analyst sentiment, MarketBeat reports on September 15, 2026 that Bristol Myers Squibb currently carries a consensus rating of Moderate Buy, with an average price target of USD 66.33 across the covered analysts. With the NYSE closing price at USD 64.08 on September 14, 2026 per the same MarketBeat data and an earlier Ad-hoc-news summary, the stock is trading about USD 2.25, or roughly 3.5 percent, below that USD 66.33 consensus target, leaving a modest distance for potential upside if forecasts are met and sentiment remains supportive.
A more cautious tone emerges in other commentary. An analysis reproduced on September 15, 2026 by Note.com highlights that Morgan Stanley analyst Terence Flynn has an underweight rating on Bristol Myers Squibb and set a price target of USD 40 based on a multiple of seven times a projected EPS of USD 5.72 for the 12-month period from late 2027 to mid-2028. That target stands markedly below both the current share price and the consensus level near USD 66, illustrating the spread of views on how patent expirations and future earnings might reshape the valuation.
The same Note.com piece points out that Bristol Myers Squibb’s stock had closed at USD 64.10 on September 14, 2026, and that this level represented a 38.3 percent increase over the prior year’s price, as well as an approximately 60 percent gain from the 52-week low of USD 42.60 registered on October 29, 2025 to the 52-week high of USD 68.09 observed on September 3, 2026. With the latest close of about USD 64.10 sitting USD 3.99, or roughly 5.9 percent, below that USD 68.09 high, the shares remain closer to the top of their 52-week range than to the bottom, which for many investors signals that the market has already priced in a good portion of the recent positive developments.
Patent risks and longer-term revenue projections
For the medium term, product-cycle and patent considerations are crucial. The Note.com analysis citing Morgan Stanley underscores that Bristol Myers Squibb faces notable patent expirations over the coming years, including the loss of U.S. exclusivity for the blockbuster anticoagulant Eliquis in 2026. According to Note.com, Morgan Stanley projects that Bristol Myers Squibb’s annual sales could decline from approximately USD 49.9 billion in 2026 to about USD 39.2 billion in 2028, a drop of roughly 21 percent over that two-year span as major products face heightened competition.
Such a projected revenue contraction, if realized, would pose a clear challenge to the stability of earnings beyond 2026. It also explains why an underweight rating with a USD 40 price target can coexist with a broader Moderate Buy consensus and a USD 66.33 average price target: the nearer-term picture anchored on 2026 guidance and recent quarterly beats appears solid, while the longer-term horizon through 2028 is clouded by the transition away from peak-patent cash flows. For investors, this divergence makes the company’s pipeline execution and launch performance a central factor in determining whether the projected revenue decline can be mitigated.
Stock performance, valuation metrics and dividend context
The same Note.com summary reports that Bristol Myers Squibb’s market capitalization stood at about USD 130.9 billion at a share price of USD 64.10 as of September 14, 2026, placing the company among the larger global biopharmaceutical names by equity value. At that price, the article cites a trailing GAAP price-to-earnings ratio of roughly 14.1 times and a lower multiple of about 9.3 times when calculated against the company’s adjusted earnings forecast for 2026, which suggests that on an adjusted basis the stock trades at a single-digit earnings multiple. For income-oriented shareholders, the same overview notes a dividend yield around 3.9 percent, based on a quarterly dividend of USD 0.63 per share highlighted by MarketBeat in its September 15, 2026 coverage.
These valuation and income figures mean that, at a closing price just above USD 64 in mid-September 2026, Bristol Myers Squibb offers a combination of moderate earnings multiple, an established dividend stream, and share-price levels that are still below both the 52-week high of USD 68.09 and the consensus price objective of USD 66.33. The contrast with Morgan Stanley’s USD 40 target underlines that the market’s current valuation incorporates expectations that the company will navigate upcoming patent cliffs more effectively than the most cautious projections suggest.
Closing price signal and trading venue
Per NYSE data relayed by MarketBeat on September 15, 2026, Bristol Myers Squibb stock closed at USD 64.08 on the New York Stock Exchange on September 14, 2026, representing a 0.69 percent increase compared with the previous session. With the shares trading in the upper half of their 52-week range and modestly below the analyst consensus target, the current price level offers a clear snapshot of how the market balances strong recent earnings with looming patent and revenue risks.
Bristol Myers Squibb stock at a glance
- Company: Bristol Myers Squibb Company
- ISIN: US0897961004
- Ticker: BMY
- Trading venue: NYSE
- Price (as of September 14, 2026, 03:59 PM): 64.08 USD
- Market capitalization: 130.9 billion USD (as of September 14, 2026)
- Sector / Industry: Health Care / Pharmaceuticals
- Index membership: S&P 500
